Oppenheimer analyst Suraj Kalia initiates coverage on Abbott Laboratories (NYSE:ABT) with a Outperform rating and announces Price Target of $130.
Oppenheimer Initiates Coverage On Abbott Laboratories With Outperform Rating, Announces Price Target of $130
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.